The newest agents to be added to the options for diabetes therapy are the sodium-glucose cotransporter 2 inhibitors (SGLT2-I), while the long-term mortality data for older people are limited they do show benefits for CVD outcomes including heart failure which may be important in treating older people (54, 55). Here, SLC5A2 is linked to heart failure.